Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
While indicated for managing type 2 diabetes, recent interest in its off-label use for obesity has surged
Government beneficiaries, including those on Medicare and Medicaid, do not qualify
Since people with diabetes are at higher risk for cardiovascular diseases, improving heart health can lessen the reliance on medications that address these risks
Food and Drug Administration (FDA) expanded the label for Wegovy (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist, approving the drug for reducing the risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke in adults who are overweight or obese with a history of CVD in the form of a previous heart attack, previous stroke, or symptomatic peripheral artery disease
US$ 27.36
US$ 23.14
US$ 26.54
US$ 29.39
US$ 20.82
